| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3388988 | A | Drug metabolism assessed as CYP3A7 (unknown origin)-mediated metabolite formation at 10 uM incubated for 60 mins in presence of NADPH by uHPLC-MS/MS method | Homo sapiens | 2 | ALA3351404 | single protein format | Scientific Literature | |
| 2. | ALA3509250 | A | Enzyme kinetics constant (Km value) for CYP3A7 was determined in human liver microsome incubated with [14C]SPP100 hemifumarate | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 3. | ALA3509259 | A | Enzyme kinetics constant (Vmax value) for CYP3A7 was determined in human liver microsome incubated with [14C]SPP100 hemifumarate | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 4. | ALA3509268 | A | Metabolic clearance (ul.min.nmol-1 CYP) of aliskiren hemifumarate for CYP3A7 was determined in human liver microsome incubated with [14C]SPP100 hemifumarate | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 5. | ALA3537744 | A | Drug metabolism assessed as recombinant CYP3A7 (unknown origin)-mediated 2-(5-chloro-4-(2-(2-chloro-4-cyclopropylphenylsulfonamido)-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenoxy)-2-fluorophenyl)acetic acid formation at 10 uM after 30 mins by LC-MS/MS analysis | Homo sapiens | 1 | ALA3526017 | single protein format | Scientific Literature | |
| 6. | ALA3537749 | A | Drug metabolism assessed as recombinant CYP3A7 (unknown origin)-mediated compound formation treated with AMG 853 at 10 uM after 30 mins by LC-MS/MS analysis | Homo sapiens | 2 | ALA3526017 | single protein format | Scientific Literature | |
| 7. | ALA3538085 | A | Drug metabolism assessed as recombinant CYP3A7 (unknown origin)-mediated 2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-(1-hydroxycyclopropyl)phenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid formation at 10 uM after 30 mins by LC-MS/MS analysis | Homo sapiens | 1 | ALA3526017 | single protein format | Scientific Literature | |
| 8. | ALA3541869 | A | Drug metabolism assessed as recombinant CYP3A7 (unknown origin)-mediated 6beta-hydroxy budesonide metabolite formation by MS/MS analysis | Homo sapiens | 1 | ALA3525921 | single protein format | Scientific Literature | |
| 9. | ALA3541872 | A | Drug metabolism assessed as recombinant CYP3A7 (unknown origin)-mediated 23-hydroxy budesonide metabolite formation by MS/MS analysis | Homo sapiens | 1 | ALA3525921 | single protein format | Scientific Literature | |
| 10. | ALA3539423 | A | Drug metabolism assessed as recombinant CYP3A7 (unknown origin)-mediated 16alpha-hydroxy prednisolone metabolite formation by MS/MS analysis | Homo sapiens | 1 | ALA3525921 | single protein format | Scientific Literature | |
| 11. | ALA3539424 | A | Drug metabolism assessed as recombinant CYP3A7 (unknown origin)-mediated delta6-budesonide metabolite formation by MS/MS analysis | Homo sapiens | 1 | ALA3525921 | single protein format | Scientific Literature | |
| 12. | ALA3539426 | A | Drug level of the compound assessed as recombinant CYP3A7 (unknown origin)-mediated metabolite formation treated with budesonide by MS/MS analysis | Homo sapiens | 4 | ALA3525921 | single protein format | Scientific Literature | |
| 13. | ALA3539729 | A | Drug metabolism assessed as recombinant CYP3A7 (unknown origin)-mediated 16alpha-hydroxy prednisolone metabolite formation by MS/MS analysis in presence of esterase inhibitor | Homo sapiens | 1 | ALA3525921 | single protein format | Scientific Literature | |
| 14. | ALA3538281 | A | Drug metabolism assessed as recombinant CYP3A7 (unknown origin)-mediated compound formation measured per nmol protein treated with AMG 853 after 15 mins by LC-MS/MS analysis | Homo sapiens | 2 | ALA3526017 | single protein format | Scientific Literature | |
| 15. | ALA3532546 | A | Time dependent inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A7 harboring human P450 oxidoreductase and b5 assessed as decrease in enzyme activity at 100 uM preincubated for 30 mins by IC25-shift assay | Homo sapiens | 1 | ALA3526089 | single protein format | Scientific Literature | |
| 16. | ALA3532654 | A | Reversible inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A7 harboring human P450 oxidoreductase and b5 | Homo sapiens | 1 | ALA3526089 | single protein format | Scientific Literature | |
| 17. | ALA3533014 | A | Activity at human recombinant CYP3A7 expressed in baculovirus-infected BTI-TN-5B1-4 insect cell microsomes assessed as metabolite formation at 5 to 100 uM after 30 mins by HPLC-RA analysis | Homo sapiens | 1 | ALA3525920 | cell-based format | Scientific Literature | |
| 18. | ALA3532331 | A | Activity at recombinant CYP3A7 (unknown origin) assessed as half life at 1 uM by LC-MS analysis | Homo sapiens | 3 | ALA3525921 | single protein format | Scientific Literature | |
| 19. | ALA4185366 | A | Substrate activity at recombinant human CYP3A7 expressed in bactosomes assessed as CYP3A7-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis | Homo sapiens | 1 | ALA4184142 | assay format | Scientific Literature | |
| 20. | ALA4687736 | A | Mixed type inhibition of human recombinant CYP3A7 expressed in baculovirus-infected insect cells using diltiazem as substrate incubated for 30 mins followed by NADPH-generating system addition by Michaelis-Menten plot analysis | Homo sapiens | 1 | ALA4680278 | cell-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!